+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
C

Actively Recruiting

Researchers are studying how to best monitor pancreatic cysts and identify biomarkers that may signal the risk of these cysts developing into pancreatic cancer. The study compares two different monitoring approaches with varying frequencies, aiming to learn which method and biomarkers help improve patient outcomes. This observational study focuses on adults aged 50 to 75 who have pancreatic cysts detected by imaging. Participants undergo either low-intensity or high-intensity surveillance programs. The low-intensity group receives MRI, CT, or endoscopic ultrasound EUS scans initially and at intervals up to every two years depending on findings. The high-intensity group has more frequent imaging based on cyst size, including regular MRI, CT, and EUS scans. Blood samples, biopsies, and fine-needle aspirations may also be collected as needed. The study follows patients for 5 years from enrollment. During the trial, participants have regular imaging tests such as MRI, CT, and EUS, along with blood sample collections to assess biomarkers related to cyst changes. Researchers monitor clinical outcomes including the development of worrisome or high-risk features, quality of life, anxiety, financial distress, and healthcare costs. The study also tracks adherence to surveillance and surgical outcomes. Follow-up continues for 5 years to capture long-term results and identify factors linked to pancreatic cyst progression.

Age: 50Years - 75YearsAll Genders
429 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
E

Actively Recruiting

Researchers are evaluating the combination of osimertinib and bevacizumab versus osimertinib alone as first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has spread beyond the lungs stage IIIB-IV and involves mutations in the EGFR gene. This phase III trial aims to determine if adding bevacizumab, which stops blood vessel growth to tumors, can better control cancer progression and improve survival compared to osimertinib alone. The study also examines overall survival, response rates, central nervous system progression, and treatment toxicity. Participants are randomly assigned to one of two groups one receives oral osimertinib daily, and the other receives oral osimertinib daily plus bevacizumab intravenously every 21 days. Treatment cycles repeat every 21 days unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo various imaging tests including echocardiography, multigated acquisition scans, computed tomography, and possibly magnetic resonance imaging. Blood and urine samples are also collected to study treatment effects and resistance mechanisms. After finishing treatment, participants are monitored every three months for up to 10 years to track disease progression and survival. The main outcome measured is progression-free survival, defined as the time from starting treatment until cancer worsens or death. Secondary outcomes include overall survival, response rates, central nervous system involvement, and treatment safety. Regular assessments and sample collections help researchers understand how the treatments work and their long-term effects.

Age: 18Years +All GendersPhase 3
604 locations
P

Actively Recruiting

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Age: 18Years +All GendersPhase 3
963 locations
P

Actively Recruiting

This trial studies adults with advanced or recurrent non-small cell lung cancer NSCLC that has a specific EGFR exon 20 insertion mutation. It aims to evaluate how well the drug osimertinib works for this condition, focusing on tumor response rates, safety, and survival outcomes. The study also explores molecular markers related to treatment response and resistance. Participants receive oral osimertinib once daily in repeating 21-day cycles, continuing until their disease progresses or side effects become unacceptable. Throughout the trial, participants undergo heart function tests echocardiography or MUGA, imaging scans MRI or CT with contrast, and blood sample collections. After treatment, follow-up visits occur at 30 days and then every three months for up to five years. During the study, researchers monitor tumor response, progression-free survival, overall survival, and any adverse events. Molecular analyses are performed on tumor tissue and circulating tumor DNA to understand treatment effects and resistance. The total participation duration can last up to five years, including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
347 locations